Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
None
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

This phase II trial studies how well the combination of ibrutinib and venetoclax works in treating patients with chronic lymphocytic leukemia whose cancer has stopped responding to ibrutinib

venetoclax
lymphoid leukemia
neutrophil count
ibrutinib
beta human chorionic gonadotrophin
  • 0 views
  • 25 Jan, 2021
  • 3 locations
None
VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib

Patients enrolled to the study will have chronic lymphocytic leukemia (CLL) and are actively receiving ibrutinib. Patients will have either been receiving ibrutinib for one year without having

chronic lymphocytic leukemia
ibrutinib
lymphoid leukemia
  • 16 views
  • 06 Aug, 2021
  • 7 locations
None
Pembrolizumab Ibrutinib and Rituximab in PCNSL

study are: Pembrolizumab (MK3475) Ibrutinib Rituximab

direct bilirubin
progestogen
follicle stimulating hormone
platelet count
hormonal contraception
  • 0 views
  • 26 Sep, 2021
None
Copanlisib Plus Ibrutinib in R/R CLL

This research study is examining the effect of adding a fixed duration of copanlisib to ibrutinib in select participants who have been on ibrutinib for at least six months for relapsed

chronic lymphocytic leukemia
lymphocytosis
platelet count
ibrutinib
lymphadenopathy
  • 0 views
  • 15 Sep, 2021
  • 1 location
None
Ibrutinib and Rituxan for Chronic GVHD

This is a phase II trial evaluating the safety and efficacy of the combination of Ibrutinib and Rituximab as primary treatment of chronic GVHD. We plan to enroll 35 patients on this study

corticosteroids
chronic graft versus host disease
immunosuppression
immunosuppressive agents
rituximab
  • 12 views
  • 07 Sep, 2021
  • 1 location
None
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

This is a phase I/II study in which patients will be enrolled in a standard 3+3 design. Once the maximum tolerated dose (MTD) is determined amongst patients with relapsed or refractory grade 1-3a follicular lymphoma, there will be a 17-patient phase II study.

  • 572 views
  • 01 Jul, 2021
  • 3 locations
None
Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia

The purpose of this study is to evaluate the impact of sequential overlapping treatment with PD-1 monoclonal antibody (mAb), pembrolizumab/MK-1375, followed by ibrutinib on endogenous immune

lymphoid leukemia
ibrutinib
monoclonal protein
monoclonal antibodies
  • 1 views
  • 14 Aug, 2021
  • 1 location
None
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer

30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease. Thus, improved therapeutic approaches are needed in this patient population. Enhancing the patient's anti-tumor immune response prior to surgery may improve long-term outcomes following RP.

adenocarcinoma
biopsy of prostate
platelet count
adenocarcinoma of prostate
prostatectomy
  • 2 views
  • 08 May, 2021
  • 2 locations
None
Ibrutinib Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia

(ibrutinib), a second generation monoclonal antibody versus CD20 (obinutuzumab) and a BCL-2 inhibitor (venetoclax) as treatment of first or second line in CLL. Objective: Negativize

chronic lymphocytic leukemia refractory
venetoclax
TP53
monoclonal protein
tyrosine
  • 0 views
  • 23 Jan, 2021
  • 2 locations
None
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate

mantle cell lymphoma
ibrutinib
rituximab
btk inhibitor
prednisone
  • 23 views
  • 30 Jul, 2021
  • 11 locations